Navidea Biopharmaceuticals, Inc. is a precision medicine company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. The Company is developing multiple precision-targeted products based on the Manocept platform. The Manocept platform serves as the molecular backbone of Lymphoseek (technetium Tc 99m tilmanocept) injection, the first product developed by the Company based on the platform. Lymphoseek is a receptor-targeted, small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients. NAV4694 is a fluorine-18 radiolabeled PET imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer’s disease (AD) and mild cognitive impairment. NAV5001 is an iodine-123 radiolabeled SPECT imaging agent being developed as an aid in the diagnosis of Parkinson’s disease (PD) and other movement disorders.
